BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026

Core Insights - BIOQUAL, Inc. reported a revenue of $20,834,840 for the six months ended November 30, 2025, which represents a decrease from $23,165,920 in the same period of 2024 [1] - The company experienced a loss before income tax of $532,917 for the six months ended November 30, 2025, compared to a loss of $2,604,227 in the prior year [1] - The net loss for the six months ended November 30, 2025, was $386,117, significantly improved from a net loss of $1,887,527 in the same period of 2024 [1] - Basic earnings per share of common stock improved to $(0.43) for the six months ended November 30, 2025, compared to $(2.11) for the same period in 2024 [1] Financial Performance - Revenue for the three months ended November 30, 2025, was $10,979,441, down from $11,395,438 in the same quarter of 2024 [1] - Loss before income tax for the three months ended November 30, 2025, was $(189,485), an improvement from $(1,672,402) in the same quarter of 2024 [1] - The net loss for the three months ended November 30, 2025, was $(137,285), compared to $(1,212,202) in the same quarter of 2024 [1] - Basic earnings per share for the three months ended November 30, 2025, was $(0.15), an improvement from $(1.36) in the same quarter of 2024 [1]